Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
6,235,531
-
Number of holders
-
45
-
Total 13F shares, excl. options
-
8,560,457
-
Shares change
-
+5,498,560
-
Total reported value, excl. options
-
$3,199,859
-
Value change
-
+$2,039,021
-
Put/Call ratio
-
1.72%
-
Number of buys
-
17
-
Number of sells
-
-24
-
Price
-
$0.3739
Significant Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) as of Q4 2024
56 filings reported holding BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q4 2024.
BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) has 45 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 8,560,457 shares
.
Largest 10 shareholders include ARMISTICE CAPITAL, LLC (4,315,000 shares), UBS Group AG (1,276,893 shares), VANGUARD GROUP INC (1,187,466 shares), BlackRock, Inc. (380,608 shares), GEODE CAPITAL MANAGEMENT, LLC (311,965 shares), WELLS FARGO & COMPANY/MN (199,010 shares), MILLENNIUM MANAGEMENT LLC (104,972 shares), RENAISSANCE TECHNOLOGIES LLC (77,900 shares), STATE STREET CORP (77,149 shares), and NORTHERN TRUST CORP (73,909 shares).
This table shows the top 45 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.